Trials / Unknown
UnknownNCT02735629
Antagonism of Opioid-Induced Respiratory Depression by CX1739 With Preservation of Opioid Analgesia
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 18 (actual)
- Sponsor
- RespireRx · Industry
- Sex
- Male
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
The study is an investigation to assess the capacity of ascending doses of CX1739 to antagonize the respiratory depressive effect of remifentanil. The study will also investigate whether ascending doses of CX1739 reduce the analgesic effect of remifentanil or alter the BIS measure of sedation and will evaluate the safety of CX1739 when used in conjunction with remifentanil.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CX1739 - 300 mg | Ampakine CX1739 - 300 mg |
| DRUG | CX1739 - 600 mg | CX1739 - 600 mg |
| DRUG | CX1739 - 900 mg | CX1739 - 900 mg |
| DRUG | Placebo | Placebo to 300 mg CX1739 |
Timeline
- Start date
- 2016-03-01
- Primary completion
- 2016-08-01
- Completion
- 2016-09-01
- First posted
- 2016-04-13
- Last updated
- 2016-07-28
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02735629. Inclusion in this directory is not an endorsement.